share_log

BRIEF-Oncolytics Biotech Reports Preclinical Data Demonstrating Synergistic Anti-Cancer Activity Of Pelareorep Combined With Car T Cell Therapy In Solid Tumors

BRIEF-Oncolytics Biotech Reports Preclinical Data Demonstrating Synergistic Anti-Cancer Activity Of Pelareorep Combined With Car T Cell Therapy In Solid Tumors

Brief-Oncollytics Biotech報告臨牀前數據顯示Pareorep聯合CAR T細胞治療實體瘤具有協同抗癌活性
Reuters ·  2021/02/23 20:23

Feb 23 (Reuters) - Oncolytics Biotech Inc ONC.TO :

路透2月23日電-Oncolytics Biotech Inc.ONC.TO：

* ONCOLYTICS BIOTECH REPORTS PRECLINICAL DATA DEMONSTRATING SYNERGISTIC ANTI-CANCER ACTIVITY OF PELAREOREP COMBINED WITH CAR T CELL THERAPY IN SOLID TUMORS

*Oncolytics生物技術報告臨牀前數據顯示，Pelareorep聯合CAR T細胞治療在實體瘤中具有協同抗癌活性

* ONCOLYTICS BIOTECH INC - MAYO CLINIC SHOWS PELAREOREP VASTLY IMPROVED PERSISTENCE AND EFFICACY OF CAR T CELL THERAPY LEADING TO CURES IN MODEL

*Oncolytics Biotech Inc-Mayo診所顯示，Pelareorep極大地提高了CAR T細胞治療的持久性和有效性，從而治癒了In模型

* ONCOLYTICS BIOTECH INC - PELAREOREP&aposS SYNERGISTIC EFFECTS WITH CAR T THERAPY APPEAR TO BE SPECIFIC AND WERE NOT OBSERVED WITH ONCOLYTIC VIRUS VSV

*Oncolytics Biotech Inc-pelareorep&aposS與CAR T治療的協同效應似乎是特異的，在溶瘤病毒VSV中沒有觀察到

* ONCOLYTICS BIOTECH INC - RESULTS DEMONSTRATE POTENTIAL OF PELAREOREP TO BROADEN APPLICABILITY OF CAR T CELLS TO SOLID TUMORS

*Oncolytics Biotech Inc-結果表明，Pelareorep有潛力擴大CAR T細胞對實體腫瘤的適用性

Source text for Eikon: Further company coverage:

Eikon的源文本：進一步的公司報道：

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論